- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Avacincaptad Pegol
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Macular Edema
- Interventions
- Faricimab, Ranibizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more
- Conditions
- Macular Degeneration
- Interventions
- 0.5 mg ranibizumab
- Drug
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Alflibercept
- Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Von Hippel-Lindau Syndrome
- Interventions
- Ranibizumab, E10030
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Macular Edema
- Interventions
- Intravitreal ranibizumab 0.3mg
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Oxnard, California • Palmdale, California + 3 more
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
- Conditions
- Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Device · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 52
- States / cities
- Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 47 more
- Conditions
- Macular Edema With Central Retinal Vein Occlusions
- Interventions
- Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Ocular Histoplasmosis Syndrome
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Retina Associates of Kentucky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Retinal Diseases, Telangiectasis
- Interventions
- ranibizumab 2.0mg
- Drug
- Lead sponsor
- Eye Center of Northern Colorado, P.C.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab, dexamethasone and verteporfin, Ranibizumab
- Drug
- Lead sponsor
- Bay Area Retina Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- ranibizumab (Lucentis(R))
- Drug
- Lead sponsor
- Lawrence S. Morse, MD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Retinal Ischemia
- Interventions
- Panretinal Photocoagulation, Panretinal Photocoagulation and intravitreal injection of ranibizumab
- Procedure
- Lead sponsor
- Southern New England Retina Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Corneal Neovascularization
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 50
- States / cities
- Artesia, California • Beverly Hills, California • Irvine, California + 42 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- E10030
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Macular Edema
- Interventions
- Vamikibart, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Arcadia, California • Torrance, California • Walnut Creek, California + 7 more
- Conditions
- Diabetic Macular Edema
- Interventions
- iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Exudative Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Rishi Singh
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Retinal Vein Occlusion
- Interventions
- Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation
- Drug · Procedure
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- combination ranibizumab + bromfenac, ranibizumab injection alone
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Choroidal Melanoma
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts